David S. Tierney, MD, currently serves as CEO of Icon Bioscience Inc., a privately held ophthalmic drug delivery company. Previously, Dr. Tierney served as President and Chief Operating Officer and Director of Oceana Therapeutics, Inc., which was acquired by Salix Pharmaceuticals, Inc. in December 2011. Previously, Dr. Tierney was the President, Chief Executive Officer and a director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine. Dr. Tierney also serves on the board of directors of Bioject Medical Technologies, Inc.
What is David S. Tierney's net worth?
The estimated net worth of David S. Tierney is at least $7.55 million as of August 21st, 2024. Dr. Tierney owns 348,874 shares of Catalyst Pharmaceuticals stock worth more than $7,553,122 as of December 17th. This net worth evaluation does not reflect any other investments that Dr. Tierney may own. Learn More about David S. Tierney's net worth.
How do I contact David S. Tierney?
Has David S. Tierney been buying or selling shares of Catalyst Pharmaceuticals?
David S. Tierney has not been actively trading shares of Catalyst Pharmaceuticals during the last ninety days. Most recently, David S. Tierney sold 15,000 shares of the business's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a transaction totalling $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. Learn More on David S. Tierney's trading history.
Who are Catalyst Pharmaceuticals' active insiders?
Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 440,755 shares worth more than $8,352,888.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company.
Learn More about insider trades at Catalyst Pharmaceuticals. Information on this page was last updated on 12/10/2024.
